Skip Navigation
Department of Health and Human Services www.hhs.gov
  • CME/CE Activities
  • Noninvasive Technologies for the Diagnosis of Coronary Artery Disease in Women
 
This website is iPhone friendly.

This CME/CE activity is provided by PRIME Education, Inc. (PRIME®) and is accredited for a multi-disciplinary audience of health care practitioners. This activity is supported by contract number HHSA290201200021I from the Agency for Healthcare Research and Quality. User data collected through this activity will reside on PRIME's educational portal for use by AHRQ.

Comparative Effectiveness Research: Noninvasive Technologies for the Diagnosis of Coronary Artery Disease in Women

To Receive a Certificate for This Activity:

Course Image
  1. 1. Read the Program Overview on this page.
  2. 2. Review the Faculty Biographies, Accreditation Statements, and Disclosure tabs.
  3. 3. Access the Activity in full.
  4. 4. Complete the Post-Test & Evaluation.
  5. 5. A printable certificate will be available immediately following the activity.

Program Overview

Activity Description

Cardiovascular disease is the leading cause of mortality for women in the United States. There are a variety of noninvasive diagnostic techniques (NITs) available for women at intermediate-risk with contraindications to invasive catheterization, or those at increased risk for complications with invasive screening.

The Agency for Healthcare Research and Quality (AHRQ) commissioned a comparative effectiveness review of published studies to assess the overall accuracy, the predictors influencing test accuracy and risks of NITs for diagnosing coronary artery disease (CAD) in women with symptoms suspicious for CAD. AHRQ also assessed the ability of NITs to risk stratify, provide prognostic data and influence clinical outcomes. This video presents the evidence obtained from the AHRQ systematic reviews and utilizes case-based interactions to assist in making informed clinical decisions regarding diagnosing cardiovascular disease in women.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Assess the benefits and harms of NITs for diagnosing coronary artery disease (CAD) in women
  • Evaluate the role of NITs in providing risk stratification and accurate prognosis and diagnosis in patients presenting with CAD symptoms
  • Apply the AHRQ findings to guide effective, patient-centered treatment and management decisions

Target Audience

This CME activity is designed to meet the educational needs of physicians, physician assistants, pharmacists, nurse practitioners, nurses, case managers, and health education specialists.

Method of Participation

To receive a certificate for this activity, you should:

  • Complete the learner assessment pretest
  • View the entire activity online
  • Complete an online evaluation & post-test
  • Print your certificate online

The estimated time to complete this activity, including review of the materials, is 1.0 hour.

Term of Approval

June 30, 2012 through June 29, 2014. Original release date: June 30, 2012.

Acknowledgement of Support

There is no fee for this CME/CE activity. This activity is sponsored by PRIME Education, Inc (PRIME®) and funded under contract HHSA290201200021I from the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health and Human Services (HHS).

Faculty Biographies and Disclosures

Click faculty name to view full biography.

Speaker

Manesh R Patel, MD
Assistant Professor of Medicine
Division of Cardiology
Duke Clinical Research Institute
Durham, North Carolina

Planner

Carolyn LePage, PhD, ARNP
Assistant Professor
Barry University School of Nursing
Miami Shores, FL

Planner

Heidi Wynn Maloni, PhD, ANP-BC, CNRN, MSCN
National Clinical Nursing Director
Department of Neurology
Multiple Sclerosis Center of Excellence, East
Veterans Affairs Medical Center
Adjunct Faculty
Trinity Nursing Program School of Professional Studies
Trinity Washington University
Clinical Preceptor and Instructor
Advanced Practice Programs
The Catholic University of America School of Nursing
Washington, DC

Planner

Michele B Kaufman, PharmD, CGP, RPh
President, PRN Communications Inc.
Editor, Pharmacovigilance Forum, P&T Journal
NYCSHP Secretary
Adjunct Faculty
Touro College of Pharmacy
New York, NY

Planner

Wanda F Carter, MPH, CHES
Adjunct Professor, Kaplan University Master of Public Health Program
Adjunct Professor, Axia College (U of Phoenix) Health Care Administration Program
Adjunct Professor, LA College International Health Care Administration Program
Adjunct Professor, Ashford University Health Care Administration Program
PHPS Alumnus, CDC Scientific Education and Professional Development Program Office

Peer Reviewer

Mori J Krantz, MD, FACC
Associate Professor of Cardiology
University of Colorado
Director, Cardiovascular Risk Reduction Program
Denver Health
Director, Cardiac Rehabilitation
Colorado Prevention Center
Denver, CO

Peer Reviewer

Joyce M Knestrick, PhD, CRNP, FAANP
Coordinator of Graduate Education
Frontier School of Midwifery and Family Nursing
Certified Family Nurse Practitioner
The Primary Care Center
Mt Morris, PA

Peer Reviewer

Debbie DeMuria, PharmD, RPh
Clinical Pharmacist
Consultant, Regulatory Affairs
Southborough, MA

Peer Reviewer

Kathleen A Jarvis, MS, RN, CCM
Clinical Educator
Alere Healthcare
Fort Lauderdale, FL

Begin Activity

Accreditation/Credit Designation

Physician Credit Designation Statement

A C C M E Logo

PRIME Education, Inc. (PRIME®) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

PRIME® designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Physician Assistant Accreditation Statement

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 1.0 hours of Category I credit for completing this program.

Nurse Practitioner Accreditation Statement

Nurse Practitioner Logo

PRIME Education, Inc (PRIME®) is approved as a provider of Nurse Practitioner Continuing Education by the American Association of Nurse Practitioners. Provider number: 060815. This program is accredited for 1.0 contact hour. Program ID# CER35.

This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.

Pharmacist Accreditation StatementA C P E Logo

PRIME® is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This curriculum has been approved for 1.0 contact hour (0.1 CEUs) by PRIME®. The Universal Activity Number for this program is 0255-0000-12-024-H01-P. This learning activity is Knowledge-Based.

Nurse Accreditation StatementA N C C Logo

PRIME Education, Inc. (PRIME®) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

PRIME® designates this activity for 1.0 contact hour.

Case Manager Accreditation Statement

The Commission for Case Manager Certification designates this educational activity for 1.0 contact hour for certified case managers.

Certified Health Education Specialist Accreditation Statement

Sponsored by PRIME Education, Inc. (PRIME®), a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc.

This program is designated for Certified Health Education Specialists (CHES) to receive up to 1.0 Category I contact hours in health education.

CHES Provider Number: MEP3774

Begin Activity

Faculty Disclosures

Faculty Name
Advisory Board Consultant Grants / Research Salary / Contractual Supported Promotional Education Stock / Shareholder Other Financial Support
Manesh R Patel, MD
Planner
None None None None None None None
Carolyn LePage, PhD, ARNP
Planner
None None None Barry University None None None
Heidi Wynn Maloni, PhD, ANP-BC, CNRN, MSCN
Planner
Consensus Management None None None None None None
Michele B Kaufman, PharmD, CGP, RPh
Planner
None OrthoMcNeil Janssen None None None None None
Wanda F Carter, MPH, CHES
Planner
None None None None None None None
Mori J Krantz, MD, FACC
Reviewer
None None GSK, GE Healthcare None None None None
Joyce M Knestrick, PhD, CRNP, FAANP
Reviewer
None None None None None None None
Debbie DeMuria, PharmD, RPh
Reviewer
None Millennium Pharmaceuticals, Inc None None None None None
Kathleen A Jarvis, MS, RN, CCM
Reviewer
None None None None None None None
Chris R Prostko, PhD
Scientific Program Director
NoneNoneNonePRIME®NoneNoneNone
Lynn Goldenberg, RN, BSN
Director of Accreditation & Compliance
NoneNoneNonePRIME®NoneNoneNone

Disclosure Policy

PRIME Education Inc (PRIME®) endorses the standards of the ACCME, as well as those of the AANP, ANCC and ACPE, that require everyone in a position to control the content of a CME/CE activity to disclose all financial relationships with commercial interests that are related to the content of the CME/CE activity. CME/CE activities must be balanced, independent of commercial bias and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when individuals in a position to control the content of CME/CE have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.

PRIME® willidentify, review and resolve all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff are provided with this activity.

Presentations that provide information in whole or in part related to non FDA approved uses of drugs and/or devices will disclose the unlabeled indications or the investigational nature of their proposed uses to the audience. Participants should refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. Participants should verify all information and data before treating patients or employing any therapies prescribed in this educational activity. The opinions expressed in the educational activity are those of the presenting faculty and do not necessarily represent the views of PRIME®, the ACCME, AANP, ACPE, ANCC and other relevant accreditation bodies.

Content validation methods are consistently utilized by PRIME® to ensure that all program content is evidence-based, fair-balanced, and developed with scientific rigor and integrity. All clinical recommendations are based on evidence accepted within the medical profession. All scientific research referred to, reported or used to support a clinical recommendation conforms to accepted standards of experimental design, data collection and analysis. In addition to review of content by course directors and expert faculty, content is also validated through independent peer reviewers selected for their expertise in the content area, as well as their experience in the intended audience. All peer reviewers, planners, course directors, faculty and relevant staff utilized by PRIME® complete disclosures which are related to their role in the educational activity.

Accessibility

PRIME®is committed to providing access to our CME programs for individuals with disabilities as identified in Section 508 of the Rehabilitation Act for all web-based programs. This website is 508 compliant.

Begin Activity

Pretest

To access the activity, please complete this brief Pretest.

  • Returning user? Login Here!
  1. Before accessing this educational activity, were you aware of the AHRQ-supported comparative effectiveness research on noninvasive technologies for the diagnosis of CAD in women?

  2. Which of the following statements is true regarding coronary artery disease in women and men?

  3. What are the advantages of an echocardiography (ECHO) over electrocardiography (ECG) in diagnosing CAD?

  4. How would you describe your current level of confidence in applying comparative effectiveness research on noninvasive technologies for the diagnosis of CAD in women?

  5. How valuable is comparative effectiveness research on noninvasive technologies for the diagnosis of CAD in women in making patient-centered diagnosis and management decisions?

  6. If you had a clinician summary/consumer summary on noninvasive technologies for the diagnosis of CAD in women, what would you most likely do?

  7. A 57-year-old female presents for a cardiovascular evaluation at the recommendation of her primary care provider. She complains of occasional chest pain. She has diabetes and no history of hypertension or dyslipidemia. She also stopped smoking 2 years ago. Her weight is 189 lb, and she is 5′7″ tall (BMI = 29.6 kg/m2). On examination, her blood pressure is 138/88 mmHg with a heart rate of 90 bpm. The ECG reveals normal sinus rhythm with non-specific ST changes. She is concerned as her mother died at the age of 65 from myocardial infarction (MI). Which of the following statements from the AHRQ review regarding the diagnosis of CAD in women is most appropriate in helping guide the physician which diagnostic testing should be performed on this patient? (choose all that apply)

Post-Test & Evaluation

You must access the activity before receiving credit!

Clinician & Consumer Summaries on Coronary Artery Disease

Download these free summaries for your reference and/or patient handouts. You may also order bulk copies free of charge from the AHRQ Publication Clearinghouse below.

AHRQ Clearinghouse Bulk Order Form

Returning user? Login Here
  • (Limit 200)
  • (This answer helps stop spam )
  • Alternatively, you can call the AHRQ Publications Clearinghouse at 1-800-358-9295. Reference the title and product number above.